Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment by Roccarina, D
Davide Roccarina, Matteo Garcovich, Maria Elena Ainora, Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini, 
Maria Assunta Zocco
Davide Roccarina, Matteo Garcovich, Maria Elena Ainora, 
Laura Riccardi, Maurizio Pompili, Antonio Gasbarrini, Maria 
Assunta Zocco, Department of Internal Medicine, Catholic 
University of Sacred Heart, 00168 Rome, Italy
Author contributions: Roccarina D contributed to the revision 
of the literature and to the drawing up the review; Garcovich M 
contributed to the revision of the literature, to the revision of the 
English and to the figures; Ainora ME contributed to revision of 
the literature and to the bibliography; Riccardi L and Pompili M 
contributed to the revision of the review; Gasbarrini A contributed 
to final approval of the article to be published; Zocco MA 
contributed to the revision of the review, to the revision of the 
English and to the final approval of the article to be published.
Conflict-of-interest statement: Davide Roccarina has not 
received any source of support in the form of grants, equipment 
or drugs; Matteo Garcovich as not received any source of support 
in the form of grants, equipment or drugs; Maria Elena Ainora 
has not received any source of support in the form of grants, 
equipment or drugs; Laura Riccardi has not received any source 
of support in the form of grants, equipment or drugs; Maurizio 
Pompili has not received any source of support in the form of 
grants, equipment or drugs; Antonio Gasbarrini has not received 
any source of support in the form of grants, equipment or drugs; 
Maria Assunta Zocco has not received any source of support in 
the form of grants, equipment or drugs. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Dr. Davide Roccarina, Department of 
Internal Medicine, Catholic University of Sacred Heart, Largo A. 
Gemelli, 8, 00168 Rome, Italy. davideroccarina@gmail.com
Telephone: +39-06-30156018
Fax: +39-06-35502775
Received: December 2, 2014   
Peer-review started: December 4, 2014   
First decision: February 7, 2015
Revised: June 15, 2015 
Accepted: July 11, 2015 
Article in press: July 14, 2015
Published online: July 18, 2015
Abstract
In the last years, the development in the oncology field 
has been huge and rapid. In particular, the evaluation 
of response to anti-tumour treatments has been being 
object of intense research, producing significant changes. 
Response assessment after therapy in solid neoplasias 
has always used radiological imaging techniques, 
with tumour size reduction representing a presumed 
therapeutic efficacy. However, with the introduction 
of anti-angiogenetic drugs the evaluation of tumour 
size has become unsuitable because some tumours, 
under treatment, show only tumour perfusion changes 
rather than lesion shrinkage. Between different imaging 
techniques with contrast-enhancement, contrast-
enhanced ultrasound (CEUS) and, in particular, dynamic 
CEUS have arisen as a promising and non-invasive 
device for monitoring cancer treatments. Moreover, the 
introduction of perfusion software has even more refined 
the technique since it is able to provide quantitative 
parameters related to blood flow and blood volume that 
can be associated with tumour response and clinical 
outcome such as the progression free survival and the 
overall survival. Here, we give an overview of the current 
status of CEUS in monitoring hepatocellular carcinoma 
response to different kind of treatments. 
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Core tip: Hereby we present a literature revision about 
the current status of contrast enhanced ultrasound in 
monitoring hepatocellular carcinoma response to different 
kind of treatments. This is a very important topic because 
of the rapid development in the oncology field due to 
the introduction of novel anti-cancer therapies. Among 
different contrast enhanced imaging techniques, dynamic 
contrast-enhanced ultrasound has emerged as a versatile 
tool as standard radiological imaging has become 
unsatisfactory.
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INTRODUCTION
The potential applications of ultrasound (US) imaging in 
the oncology field are vast, ranging from early cancer 
detection and tumour characterisation to treatment 
response monitoring[1]. In the last years, the evaluation 
of response to anti-tumour treatments has been being 
object of intense investigations and changes, since a 
number of new anti-cancer agents are progressively 
becoming available[2-4]. In this setting a proper evaluation 
of tumour response is very important in the achievement 
of therapeutic decisions.
Until now the classical response assessment criteria 
in solid cancers were based on tumour size measure-
ment by radiological imaging techniques and a reduction 
in tumour size during treatment was associated with 
therapeutic and clinical benefit. However, with the 
recent development of molecularly targeted therapies it 
has become necessary to introduce different methods 
to evaluate treatment efficacy. To achieve this goal, 
the traditional response criteria based on tumour size 
[Response Evaluation Criteria In Solid Tumours (RECIST)] 
were lately modified introducing new criteria that 
evaluate changes in tumour vascularisation[5]. 
Among different contrast-enhanced imaging techni-
ques, contrast-enhanced US (CEUS) and dynamic CEUS 
(D-CEUS) have arisen as a promising, non-invasive and 
cost-effective device for monitoring cancer treatments. 
Moreover, the introduction of perfusion software has 
refined the technique even more since it is able to 
provide quantitative parameters related to blood flow 
and blood volume[5-8].
The present review focused on the current standards 
and perspectives of application of both CEUS and 
D-CEUS in the evaluation of treatment response in 
patients affected from hepatocellular carcinoma (HCC).
HCC AND CEUS
Liver cancer is the sixth most common cancer, the third 
cause of cancer related death, and accounts for 7% of 
all cancers. HCC represents more than 90% of primary 
liver cancer, is a major global health problem and its 
worldwide incidence is growing up[9].
Diagnosis of HCC can be done using histopathology 
or by identifying the typical vascular hallmark (hyper-
vascular in the arterial phase with washout in the portal 
venous or delayed phases) using contrast-enhanced 
imaging techniques.
The treatment depends on the tumour stage at 
the moment of the diagnosis. Liver resection, liver 
transplantation and ablative procedures such as radio-
frequency ablation (RFA) and percutaneous ethanol 
injection (PEI) are curative. Trans-catheter arterial 
chemo-embolisation (TACE) and systemic therapies 
such as anti-angiogenetic drugs and chemotherapies 
represent palliative treatments[10].
The advent of microbubble US contrast agents (UCA) 
has allowed the display of parenchyma microvasculature, 
impossible with B-mode and color-Doppler method[11]. 
The enhancement patterns of the tumours can be studied 
during arterial, portal venous, late and post-vascular 
phases, in real time and with a higher temporal resolution 
compared to other imaging modalities, allowing a deeper 
study of the lesion enhancement behavior. Moreover, the 
good safety profiles of UCA make possible to administer 
repeated boluses during the same exam, if necessary.
Recent European Federation of Societies for Ultra-
sound in Medicine and Biology (EFSUMB) guidelines 
highlighted the role of CEUS, as a cost-effective technique 
with a good safety profile, not only in the characterisation 
and detection of focal liver lesion but also in monitoring 
tumour response after curative, loco-regional and 
systemic HCC treatments[12,13].
CEUS AND TUMOUR RESPONSE
An accurate evaluation of treatment efficacy is funda­
mental both for phases Ⅱ and Ⅲ clinical trials and for 
clinician as a guide for therapeutic decisions. 
When we evaluate the role of CEUS in monitoring 
tumour response it is important to distinguish between 
morphological and functional response.
In the first case vascular changes produced by the 
treatment are evaluated according modified-RECIST 
(mRECIST) by a qualitative or semi-quantitative CEUS. 
On the contrary, functional response can be assessed 
by D-CEUS that combines morphological and functional 
data leading to a more accurate measurement of tumour 
characteristics. The kinetics of microbubble flow through 
the tumour is evaluated by mathematical models applied 
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to signal intensity vs time able to provide quantitative 
parameters associated to blood flow and blood volume. 
This application has encouraging clinical potential for 
delineating changes in tumour vascularisation secondary 
to anti-angiogenetic treatment[5-8]. 
CEUS AND ABLATIVE TREATMENTS: 
RFA AND PEI
All ablative procedures cause the destruction of both the 
tumour itself and its vasculature by alterations in the 
target lesions such as coagulative necrosis, apoptosis 
and tissue granulation. Contrast-enhanced computed 
tomography (CE-CT) performed 4-6 wk after the treat-
ment is currently considered the “gold standard” for the 
evaluation of tumour response.
Tumour necrosis is identified according to the absence 
of hyper-enhancement areas in the context of the treated 
lesion[10].
Due to the ability in representing HCC micro-vessels, 
CEUS has been utilised to evaluate intra-tumoral 
vascularisation after ablative treatments. Response is 
complete when the tumour treatment has determined a 
coagulative and vascular necrosis of the entire lesion and 
in this case no contrast enhancement is detected during 
all contrastographic phases of the dynamic study. On 
the contrary, when the therapy has failed zones of well-
perfused residual tumour remain in the target lesion and 
focal contrast enhancement is detected in these areas. 
The residual unablated tumour appears like an irregular, 
eccentric or nodular peripheral enhancement[14-17]. 
Sometimes, especially in HCC treated with PEI, septa 
enhancement as well as a vessel passing through the 
nodule may be detected.
In large tumours, incomplete ablations might look 
as zones with contrast up-taking, which usually are 
localised nearby the periphery of the lesions. In these 
cases, an accurate comparison between the pre- and 
post-ablation images is necessary to achieve a correct 
evaluation of treatment efficacy[17].
Timing strategy 
No unanimous strategy exists concerning the most 
appropriate timing schedule for the performance of 
CEUS. In fact, in the currently available studies on this 
topic CEUS has been performed at very heterogeneous 
time-points after the ablative treatments. In particular, 
tumour response can be evaluated in the immediate 
post-treatment, after 1 d, 1 mo or later during the follow-
up[18].
Immediate post-treatment assessment
The possibility to detect the residual enhancing tumour 
immediately after ablation by means of CEUS could be a 
tempting approach in the interventional setting as it may 
lead to a prompt retreatment in the same session[19]. In 
fact, when CEUS is carried out within 60 min after PEI or 
RFA, there is a fair agreement with standard radiological 
imaging performed 2 or 4 wk later. However, despite its 
high specificity (94%), CEUS is characterised by only 
40% of sensitivity in the detection of viable remnant 
tumour, due to false negative results. This high number 
of false negative cases could be related to the difficult 
interpretation of the images obtained immediately after 
the procedure and, especially, to the presence of a 
thin marginal area of hyper-vascularity in the arterial 
phase not followed by a proper washout in the portal/
venous phase[15]. More specifically, the
differentiation between the hyper-vascularity produced 
by a localised tissue response (hyperemia) or arteriove-
nous shunting and the residual hypervascular tumour in 
the periphery of the ablated area may be challenging. 
Reactive hyperemia usually shows a diffuse and homo-
geneous peripheral enhancement, with uniform and ring-
like thickness, no more than 4-5 mm thick, followed 
by iso-enhancement in the portal and late phase. In 
contrast, residual tumour shows a local, heterogeneous 
or irregular peripheral enhancement, a thickness 
greater than 7-8 mm and the pattern of enhancement 
is characterised by hyper-enhancement in the arterial 
phase, followed by hypo-enhancement in the portal 
and late phase. However, in some cases viable tumour 
could be associated with arterial enhancement without 
complete washout in the portal and late phase, usually 
likewise to the enhancement pattern of the tumour 
before treatment[20,21]. 
Other reasons justifying the high number of false 
negative results could be a scan plane not including the 
residual tumour, uncooperative patients under conscious 
sedation or general anesthesia and, finally, an incorrect 
scanning time. In fact, intra-lesional gas developing 
during RFA or PEI may hinder a proper evaluation in the 
immediate post-procedural follow-up. These artefacts 
may persist for 15-180 min[22], but a delay of at least 
20 to 40 min after the procedure would help to adjust 
visibility minimizing gas development.
Based on the results of different studies the positive 
predictive value (PPV) and negative predictive value of 
immediate post-procedural CEUS in detecting viable 
tumour tissue are around 82% and 50%, respectively[15]. 
Accordingly, the only significant role of CEUS 
performed within 60 min after treatment is to detect 
viable tumour during the same ablative session and 
allow an immediate retreatment, thereby lowering the 
rate of unsuccessful treatment, improving the cost-
effectiveness ratio and optimising patient care[23].
24 h follow-up
Some authors suggest that CEUS should be performed 
at least 24 h after RFA or PEI. However, this strategy 
seems to be less attractive than the immediate post-
treatment assessment, not permitting an ablation 
refinement in the same session if required. Moreover, as 
immediate post-procedural CEUS may not be available 
in all clinical settings, a delayed CEUS should overcome 
some of the aforementioned technical issues of intra-
operative CEUS.
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hepatic relapse[23].
However, even though several studies has been 
published regarding the role of CEUS vs CE-CT after 
ablative treatments, the results remain still controversial 
and an ideal imaging follow-up scheme is not yet 
available. Where CEUS is available both techniques 
should be recommended in order to combine the virtues 
and to reduce the limits of both modalities. Anyway, 
further studies are still needed to evaluate the efficacy 
of this approach[29]. 
CEUS AND TACE
Since TACE has been introduced as a palliative treatment 
in patients with unresectable HCC it has become one 
of the most common form of interventional therapies, 
although in many cases it is difficult to achieve complete 
necrosis of the tumour. Intratumoral vascularity after 
TACE has been shown to correlate with tumour viability 
and is used as the major criterion to assess treatment 
efficacy and to plan additional treatment.
Similarly as previously described for RFA and PEI, 
CEUS has been proved to be efficient in differentiating 
residual from necrotic tumour after TACE.
Moschouris et al[32] reported that the early assess-
ment of treatment response by CEUS performed 48 h 
after drug-eluting bed TACE could underestimate the 
degree of necrosis in comparison with delayed evaluation 
(35-40 d after the procedure) with a percentage of 
tumour necrosis of 43.5% and 52.3%, respectively. The 
same authors found a good agreement between delayed 
post-TACE CEUS and CE-CT[32].
In another study CEUS resulted even more sensitive 
than CE-CT in the detection of residual vascular enhan-
cement after TACE using angiography as reference 
standard. In fact, CE-CT performed 1 mo after treatment 
detected 20 of 23 incomplete responses whereas 
CEUS performed at the same time point detected all 
cases of incomplete response. Results of CEUS and 
CE-CT agreed with those of the reference standard 
(angiography) in 38/38 (100%) and in 35/38 (92.1%) 
nodules, respectively[33]. Another recent study from 
a Chinese group suggests a leading role of CEUS 
compared to CE-CT for detecting residual tumour after 
lipiodol-based TACE. Liu et al[34] evaluated treatment 
response in 130 HCC patients who underwent CEUS 15 
to 90 d after procedure. The sensitivity and accuracy 
of detecting residual tumour by CEUS vs CE-CT were 
95.9% vs 76.2% and 96.2% vs 77.7% respectively, 
thus recommending CEUS as an optional procedure for 
assessing the tumour response after TACE[34].
Based on these results, CEUS performed at 1-mo 
with second generation contrast agents can be regarded 
as a valid alternative technique to CE-CT in the assess-
ment of therapeutic response after TACE for HCC (Figure 
1).
Good concordance between CEUS and CE-CT per-
formed at the same time point has been reported[24,25]. 
However, a recent study shows that 1 d after the 
procedure gas bubbles could be displayed within half 
of the tumour, with a reported sensitivity in detecting 
residual viable tumour only equal to 27%. In addition, 
one patient with suspected residual disease at this time 
point was finally classified as a false positive result. 
Thus, CEUS performed at 24 h after ablative treatment 
may show both false negative and false positive results 
hampering its routine application in clinical practice[24].
These results were confirmed by Meloni et al[26], 
who found that the sensitivity and specificity of CEUS 
performed at 24 h were 33% and 98%, respectively. 
Overall, these data indicate that CE-CT and CEUS 
at 24 h are not always helpful in the evaluation of 
percutaneous ablation response, having only poor 
sensitivity and a specificity not equal to 100%.
These unsatisfactory results might be related to the 
gas persistence in the context of the tumour, as well as 
to the frequent post­treatment peritumoral inflammation. 
Both these conditions may be still detectable several 
days after treatment and, in some cases, may persist up 
to 1 or 2 mo[24].
One month follow-up
Several studies evaluated the usefulness of CEUS 
performed 1 mo after ablative therapies compared 
to the CE-CT at the same time-point. These studies 
demonstrated almost the same diagnostic accuracy 
between CEUS and CE-CT. In particular, Vilana et 
al[24] found a sensitivity and specificity of 91% and 
97%, respectively. Similarly, Pompili et al[27] reported 
a sensitivity of 87% and a specificity of 98.4%, with a 
good diagnostic agreement with CE-CT (94.6%).
Based on these results CEUS performed 1 mo 
after the procedure can be considered an appropriate, 
reliable, comparatively inexpensive and safe alternative 
technique to CE-CT in the assessment of therapeutic 
response after RFA or PEI[24,27,28]. 
Long term follow-up
A 2 years follow-up with an imaging technique is 
mandatory to detect HCC recurrence, satellites or seedi-
ng[29,30]. The ability of CEUS in detecting local tumour 
progression or new intrahepatic recurrence during 
follow-up has been evaluated in different studies. In all 
cases the sensitivity and the PPV of CEUS compared to 
CE-CT were unsatisfactory[31]. These results could be 
related to the short duration of the arterial phase that 
makes difficult to scan the whole liver or to the intrinsic 
shortcomings of US technique (small lesion, unfavorable 
location, etc.).
Thus, in the long time follow-up, CE-CT or contrast-
enhanced magnetic resonance (CE-MRI) are the 
mainstay for the imaging of treated patients and the 
detection of local or remote intra-hepatic and extra-
Roccarina D et al . CEUS in monitoring HCC therapy
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CEUS AND QUANTITATIVE 
ASSESSMENT OF FUNCTIONAL 
RESPONSE 
Tumour angiogenesis
Angiogenesis plays a critical role in the growth and 
spread of tumour. Cancer cells are able to produce 
some biochemical signals stimulating angiogenesis and 
to enhance the production of angiogenesis signaling 
molecules by the surrounding normal cells. Fed by new 
blood vessels cancer cells proliferate and progressively 
lose their differentiation, invading the around tissues, 
going in the blood and lymphatic vessels and forming 
new colonies of cancer cells far from the primitive 
cancer, called metastases[35].
The “gold-standard” to assess the angiogenesis is the 
histological evaluation of the average number of micro-
vessels [microvascular density (MVD)][36]. However, 
biopsy is invasive and sampling bias may happen due to 
tumours heterogeneity, producing a possibly under- or 
overestimation of the angiogenesis grade[37].
Furthermore, MVD is not able to give information 
about changes of blood flow or vascular bed hyper-
permeability. On the contrary, functional imaging is 
able to quantify these changes above all as an early 
consequence of the anti-angiogenesis therapy[38,39].
Anti-angiogenetic agents
One of the most important recent steps in the oncology 
field is the development of anti-angiogenetic drugs. 
These agents act interfering with various steps in the 
angiogenesis process. Usually, they bind to receptors 
on the surface of endothelial cells or to other proteins in 
the downstream signaling pathways, inhibiting factors 
needed for new blood vessels arrangement.
The United States Food and Drug Administration 
approved different drugs showing anti-angiogenetic 
activity including sorafenib, sunitinib and bevacizumab. 
To date sorafenib is the only anti-angiogenetic approved 
for HCC treatment but other drugs with similar activity 
are under investigation in many phase Ⅱ and Ⅲ trials.
Angiogenesis inhibitors interfere with various steps 
in this process. In particular, sorafenib acts by inhibiting 
the serine-threonine kinases and the receptor tyrosine 
kinase activity of vascular endothelial growth factor 
receptors (VEGFRs) and platelet-derived growth factor 
receptor β, which have been implicated in the molecular 
pathogenesis of HCC[40-45].
The different mechanism of action of these new 
agents from classical cytostatic drugs requires a shift 
from standard efficacy evaluation criteria to new 
imaging modalities that assesses changes in tumour 
vascularisation. Although progression free survival (PFS) 
and overall survival (OS) represent the most significant 
efficacy end­points in the medium and long term, early 
assessment of tumour angiogenesis remains a crucial 
aim in this area as it allows optimisation of individualised 
treatment[46]. Especially, early evaluation of failed 
response allows a tailored therapy, avoiding needless 
toxicity, psychological burden and costs.
D-CEUS
D-CEUS is a new functional technique enabling a 
quantitative assessment of solid tumour perfusion. 
This is achieved by a quantitative analysis performed 
on contrast uptake curves which are built up from raw 
linear data after automatic modelisation. The robustness 
of this approach relies on the fact that signal intensity 
is proportional to the microbubble concentration in the 
region of interest. Raw linear data are used to quantify 
parameters such as peak intensity (PI), time to PI, 
mean transit time, slope coefficient of wash­in (Tp), total 
area under the curve (AUC), AUC of wash-in and AUC 
of wash-out. All these parameters provide information 
about blood flow and volume, but an optimal parameter 
has not been clearly identified yet[47]. 
D-CEUS is supported by the French National Cancer 
Institute (INCa), which is currently evaluating such 
technique in different malignancy as well as in primary 
HCC to establish the reliable perfusion parameters and 
timing for quantitative anticancer efficacy assessments[48].
Reduction in tumour vascularisation can easily be 
detected in responders after 1 or 2 wk and is correlated 
Figure 1  Contrast-enhanced ultrasound performed after 1 mo in a 71-year-old man treated with trans-catheter arterial chemo-embolisation: On the left side 
complete necrosis is depicted as an avascular area; on the right side B-mode imaging of the treated area.
1 cm
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with mRECIST response, PFS and OS in renal cell 
carcinoma and HCC[6,47].
D-CEUS in monitoring anti-angiogenetic treatment for 
HCC
As already said, VEGF plays a critical role in mediating 
angiogenesis in HCC, and the tumour expression of VEGF 
correlates with vascular density, tumour invasiveness and 
prognosis[49-51]. Several studies demonstrated the utility 
of D­CEUS for the quantification of tumour perfusion as 
a prognostic tool in patients with advanced HCC treated 
with anti-angiogenetics and identified quantitative 
parameters correlated with standard efficacy endpoints 
such as tumour response, PFS and OS. 
In a recent experimental study D-CEUS was able 
to detect a reduction in tumour vascularisation as 
early as 3 d after bevacizumab therapy for HCC, with 
a good agreement with CE-CT performed at 2 mo in 
the identification of responders and non-responders 
patients[52]. 
Another study from our group corroborated that 
D-CEUS is a reliable method to identify early reduction in 
tumour vascularisation in patients undergoing treatment 
with sorafenib. Changes in selected quantitative 
parameters, detected after 14 d of therapy, agreed 
with tumour response evaluated by means of standard 
criteria at 2 mo. Between the parameters analysed PI, 
AUC and Tp showed a significant reduction soon after 
the beginning of therapy with sorafenib in most of the 
patients reaching long-term stable disease (Figure 2). 
Moreover, a relationship was found between D-CEUS 
variables and improved clinical outcome such as 
prolonged OS and PFS[53].
Some researchers evaluated the usefulness of 
D­CEUS in the quantification of liver parenchymal per­
fusion for the early detection of major adverse events 
in patients with advanced HCC treated with sorafenib. 
The decrease in functional parameters related to blood 
volume (AUC and PI) between baseline and day 7 after 
the initiation of treatment was strongly associated with 
changes in laboratory data related to liver function and 
was able to predict the occurrence of major adverse 
events such as liver failure[54].
The dynamic enhancement parameters of D-CEUS 
can provide important references for clinical pathological 
factors in prognosis prediction such as VEGF expression 
and MVD. In fact, a recent study reported a good 
correlation between VEGF and CD34 expression, 
(evaluated by immune-histo-chemistry), MVD and some 
D-CEUS parameters (enhanced time, washout time and 
AUC)[55].
CONCLUSION
Over the past decades, different locoregional and 
systemic therapies have emerged as a suitable alternative 
to surgery in patients with HCC. An accurate assessment 
of therapeutic response is mandatory, as complete 
A
B
Media Eoo (intensita)
Media Eoo (intensita)
Tempi di fotogramma stimati
Tempi di fotogramma stimati
Tempo assoluto
Tempo assoluto
Figure 2  Target hepatic lesion in a 65-year-old man treated with sorafenib: Clinical example of responder on dynamic contrast-enhanced ultrasound. A: 
Contrast-enhanced ultrasound with corresponding time-intensity curve at baseline; B: Fifteen days after onset of sorafenib therapy, contrast-enhanced ultrasound 
revealed an increase in tumour necrosis with drastic reduction of tumour perfusion parameters shown by contrast enhancement pattern and corresponding time-
intensity curve.
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tumour necrosis significantly increases patient survival, 
whereas residual viable tumour requires additional 
treatment. CEUS suggests an effective procedure when 
a previously enhancing, hyper-vascularised HCC tumour 
shows lack of contrast enhancement after treatment, 
whereas still viable tumoral tissue is usually visualised as 
an arterial-enhancing area with subsequent washout[6].
Several studies demonstrated the usefulness of 
CEUS and D-CEUS in monitoring tumour response 
after HCC treatment. In fact, it is able to provide both 
morphological and functional data associated with low 
cost and good safety profile. 
CEUS performed within 60 min after RFA or PEI 
with a correct timing scan seems to be reliable for 
the immediate post-treatment assessing, allowing 
an immediate retreatment during the same session, 
if necessary[23]. As concerning recently introduced 
devices for ablative treatment such as cryoablation and 
irreversible electroporation, the usefulness of CEUS was 
investigated only in few studies showing preliminary 
and inconclusive results[56]. One important information 
stemming from these studies is that CEUS pattern after 
cryoablation appears different compared to that after RFA 
because the margins of the lesions are less well defined 
and shrink significantly faster than RFA lesions, explaining 
why it is often difficult to identify them on B-mode or 
even CEUS more than 1 year after the procedure[57]. 
Overall, CEUS can be considered a reliable and safe 
alternative technique to CE-CT in the assessment of 
therapeutic response to ablative treatment and TACE 
after 1 mo[28]. 
Finally, CEUS associated with perfusion software and 
time intensity curves can be used as a new functional 
technique enabling a quantitative assessment of solid 
tumour perfusion by means of a quantitative analysis. 
This is very important in the early assessment of 
tumour vascularisation in HCC treated with vascular 
targeting agents since it would enable an optimisation 
of individualised treatment. Especially, early evaluation 
of failed response allows a tailored therapy, avoiding 
unnecessary toxicity, psychological burden and costs. 
The effective application of CEUS and D-CEUS in 
clinical practice has been recently highlighted by EFSUMB 
guidelines. For example this panel of experts recognised 
the important role of CEUS in the very early evaluation 
of ablative treatment as a guidance for immediate re-
treatment of residual unablated tumour[12].
Novel CEUS-based techniques may even exploit the 
advantages of this imaging modality in evaluating tumour 
response after HCC treatment. For instance, a technical 
development based on real-time fusion of CEUS with 
CE-CT or CE-MRI enables a precise mapping of tumour 
lesions in CEUS. This new technique allows a multi-
plane display of tumour lesions and also shows small 
lesions which are normally hard to display in standard 
US. In a pilot study by Ross et al[58] the fusion of pre-
interventional CE-CT or CE-MRI with post-interventional 
CEUS performed immediately after treatment showed 
an improved visualisation of microcirculation and residual 
tumour perfusion after TACE. A high correlation between 
early fusion study (CEUS with CE-CT or CE-MRI) and 
CE-CT performed 6 wk after TACE granted an early 
assessment of therapeutic success[58]. More recently, 
three-dimensional CEUS technique (3D CEUS) has been 
reported to improve the study of tumour vascularity, thus 
allowing the response evaluation of HCC treatments in 
the three orthogonal planes. Nevertheless, it has been 
suggested that the spatial resolution of the current 3D 
probes may be limited as 3D CEUS provided similar 
diagnostic performance compared to conventional CEUS 
in the assessment of therapeutic response of HCC treated 
with ablative treatments[59].
In conclusion, the perspectives about a large diffusion 
of CEUS and D-CEUS in clinical practice are very positive 
and promising, although further studies are warranted 
to determine the still unclear aspects such as the best 
timing and the best quantitative dynamic parameter for 
the assessment of response to HCC treatment. 
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